Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects

doi:10.3748/wjg.v20.i16.4526

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 16

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11154)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

581

WORD

349

HTML

7782

Figures (1-6)

159

Tables (1-3)

130

Sum=9001

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1207

Download

946

Sum=2153

Apr 28, 2014 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 28, 2014; 20(16): 4526-4535
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4526

Full Size Figure Download Figure

Figure 6 Drugs targeting human epidermal growth factor receptor 2 in clinical development for treatment of gastric, esophageal, or gastroesophageal junction cancer. The individual compounds are listed according to the stage of development[35].

Citation: Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535
URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4526.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4526